To enhance combination product reviews, drug fee revenue will pay for related positions in CDRH.
Drug user fees will support staff in FDA's device center for the first time beginning in fiscal year 2018.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.
Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.
